Engineering Precision in Genetic Medicines: Inside ElevateBio’s Genomic Medicine Toolbox
How ElevateBio engineers gene editors that meet the versatility, potency, and safety requirements of therapeutic gene editing programs.
Because DNA edits are permanent, therapeutic gene editing demands precision and safety that early-generation editors were never designed to deliver. This whitepaper describes how ElevateBio engineers editors against all three clinical criteria (versatility, potency, and specificity) using a curated protein catalog of more than 10 billion sequences, novel enzyme discovery, and an AI-driven optimization platform built for clinical-grade output.
What you’ll learn
- How PAM engineering across ElevateBio’s CRISPR systems addresses more than 90% of ClinVar pathogenic variants
- How LETI-101, an allele-selective preclinical nuclease editor for Huntington’s disease, demonstrates the enzyme customization that hard therapeutic targets require
- How iterative engineering and AI-driven discovery produce adenine base editors with clinical-grade specificity, including potentially novel de novo deaminases beyond what nature has produced
- How the same platform approach also supports targeted gene insertion (using engineered large serine recombinases), RT editing, and epigenetic editing
Whitepaper Download
Enter your information below to view the PDF for this whitepaper
